Harrow (HROW) Competitors $34.93 +3.56 (+11.35%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$35.48 +0.56 (+1.59%) As of 07/11/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HROW vs. SLNO, CRNX, CPRX, AMRX, RXRX, NAMS, INDV, BCRX, CNTA, and SPRYShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include Soleno Therapeutics (SLNO), Crinetics Pharmaceuticals (CRNX), Catalyst Pharmaceuticals (CPRX), Amneal Pharmaceuticals (AMRX), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Indivior (INDV), BioCryst Pharmaceuticals (BCRX), Centessa Pharmaceuticals (CNTA), and ARS Pharmaceuticals (SPRY). These companies are all part of the "med - drugs" industry. Harrow vs. Its Competitors Soleno Therapeutics Crinetics Pharmaceuticals Catalyst Pharmaceuticals Amneal Pharmaceuticals Recursion Pharmaceuticals NewAmsterdam Pharma Indivior BioCryst Pharmaceuticals Centessa Pharmaceuticals ARS Pharmaceuticals Soleno Therapeutics (NASDAQ:SLNO) and Harrow (NASDAQ:HROW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Do analysts rate SLNO or HROW? Soleno Therapeutics currently has a consensus target price of $108.70, indicating a potential upside of 33.26%. Harrow has a consensus target price of $63.83, indicating a potential upside of 82.75%. Given Harrow's higher probable upside, analysts clearly believe Harrow is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, SLNO or HROW? Harrow has higher revenue and earnings than Soleno Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.62-17.66Harrow$199.61M6.42-$17.48M-$0.56-62.38 Which has more volatility and risk, SLNO or HROW? Soleno Therapeutics has a beta of -2.63, suggesting that its share price is 363% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Does the media refer more to SLNO or HROW? In the previous week, Harrow had 2 more articles in the media than Soleno Therapeutics. MarketBeat recorded 17 mentions for Harrow and 15 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 0.87 beat Harrow's score of 0.43 indicating that Soleno Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of SLNO or HROW? 97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by insiders. Comparatively, 15.2% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is SLNO or HROW more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -10.19%. Harrow's return on equity of -25.01% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -77.52% -63.44% Harrow -10.19%-25.01%-4.27% SummaryHarrow beats Soleno Therapeutics on 9 of the 16 factors compared between the two stocks. Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.28B$2.42B$5.55B$9.11BDividend YieldN/A1.81%5.07%4.01%P/E Ratio-62.379.4228.2120.26Price / Sales6.42727.01432.0099.74Price / Cash255.45164.4637.1257.67Price / Book17.914.608.045.49Net Income-$17.48M$31.26M$3.19B$250.45M7 Day Performance9.91%4.80%3.63%4.79%1 Month Performance12.10%5.42%4.06%7.68%1 Year Performance47.95%-4.36%30.02%16.44% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow2.1908 of 5 stars$34.93+11.3%$63.83+82.7%+47.1%$1.28B$199.61M-62.37180News CoverageAnalyst ForecastSLNOSoleno Therapeutics4.6204 of 5 stars$83.78+0.6%$107.10+27.8%+83.3%$4.22BN/A-18.1330Trending NewsAnalyst ForecastCRNXCrinetics Pharmaceuticals3.4654 of 5 stars$28.76-4.0%$74.56+159.2%-39.5%$2.69B$1.04M-7.53210News CoverageAnalyst ForecastCPRXCatalyst Pharmaceuticals4.9349 of 5 stars$21.70-0.4%$32.83+51.3%+33.7%$2.65B$534.65M13.8280AMRXAmneal Pharmaceuticals3.5134 of 5 stars$8.09-0.5%$11.60+43.4%+14.9%$2.54B$2.83B-202.208,100High Trading VolumeRXRXRecursion Pharmaceuticals2.0021 of 5 stars$5.06+0.6%$7.00+38.3%-31.3%$2.06B$58.84M-2.86400Analyst ForecastOptions VolumeGap DownNAMSNewAmsterdam Pharma2.706 of 5 stars$18.11-2.5%$42.89+136.8%+2.6%$2.03B$45.56M-9.634Positive NewsINDVIndivior1.1899 of 5 stars$14.74+5.7%$17.00+15.3%+36.5%$1.92B$1.19B-47.551,051High Trading VolumeBCRXBioCryst Pharmaceuticals4.2069 of 5 stars$8.96-4.3%$16.89+88.5%+24.4%$1.87B$450.71M-34.46530CNTACentessa Pharmaceuticals3.2547 of 5 stars$13.14+0.1%$27.89+112.2%+50.8%$1.75B$6.85M-7.26200SPRYARS Pharmaceuticals3.0472 of 5 stars$17.45-4.1%$31.00+77.7%+59.2%$1.71B$89.15M-109.0690Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Soleno Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives Amneal Pharmaceuticals Alternatives Recursion Pharmaceuticals Alternatives NewAmsterdam Pharma Alternatives Indivior Alternatives BioCryst Pharmaceuticals Alternatives Centessa Pharmaceuticals Alternatives ARS Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HROW) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HROW Stock Alerts